Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: TI2, TechInvestorToo who wrote (58)	11/19/2001 6:10:32 PM
From: nigel bates	Read Replies (1) \| Respond to of 590

Anyone listen to the cc ? FREMONT, Calif.--(BW HealthWire)--Nov. 19, 2001--Abgenix, Inc. (Nasdaq:ABGX - news) announced today plans for Raymond Withy, Ph.D., to succeed R. Scott Greer as the company's chief executive officer effective in mid-2002, and to join the company's board of directors, effective immediately. Mr. Greer, who will continue as chairman of the board and as an officer of the company, will remain active in the strategic management of Abgenix. Dr. Withy, currently the company's president and chief operating officer, has been an officer of Abgenix since its founding in 1996. In his previous roles as chief business officer, and vice president, Corporate Development, he and his team were instrumental in forming corporate collaborations with more than 30 biotechnology and pharmaceutical companies. Dr. Withy was involved in the formation of Abgenix as a subsidiary of Cell Genesys, while serving as director, Business Development of Cell Genesys. ``I am very proud of what the Abgenix team has accomplished in its first five years and believe the company is well on its way to becoming a new biotech powerhouse,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``The evolution of our business toward significantly expanded product development activities fits well with Ray's technical background. After the transition, I look forward to continuing to assist Abgenix at a more macro level as executive chairman.'' ``With a strong balance sheet, world class corporate collaborations, an exciting and growing product portfolio, and our industry leading human antibody technologies, Abgenix is well-positioned to succeed,'' stated Raymond Withy, Ph.D., president and chief operating officer. ``Over the next several years, I see Abgenix building one of the most exciting product pipelines in the industry.'' Dr. Withy, 46, has over 16 years experience in the biotechnology industry. Prior to Abgenix and Cell Genesys, Dr. Withy held various research and development positions at Genzyme Corporation and Integrated Genetics, Inc. Dr. Withy received his Ph.D. in Biochemistry from the University of Nottingham in the U.K. and was a post-doctoral fellow at the California Institute of Technology. Abgenix will host a conference call to provide an update on company developments, its business objectives and clinical and pre-clinical programs. The conference call will be held today, November 19, 2001 at 4:30 PM EST. Interested parties may listen to the call by dialing 800-500-0311 and mentioning the ``Abgenix Conference Call''. A replay of the call will be available starting at 7:30 PM on November 19th through midnight on December 3, 2001. To listen to the replay, dial 888-203-1112 and enter the replay access code 793411 when prompted.